The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...
INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is ...
Basaglar (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for managing blood sugar levels in certain people. As with other drugs, Basaglar can cause side effects, such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results